Recently, the American Diabetes Association (ADA) released a set of policy recommendations to improve patient access to much-needed insulin and to lower the substantial cost to treat diabetes.
Recently, the American Diabetes Association (ADA) released a set of policy recommendations to improve patient access to much-needed insulin and to lower the substantial cost to treat diabetes.
Among the ADA’s recommendations are the following:
Competition and follow-on insulins: In the United States, follow-on insulins are currently regulated as drugs and not as biosimilars (though the ADA’s materials refer to such products as “biosimilars”). Currently, the FDA has approved 3 follow-on insulins: Admelog, Basaglar, and Lusduna, of which only Admelog and Basaglar are currently available for purchase in the United States.
Recently, the FDA published a list of medications that have lapsed in patent protection and do not have follow-on alternatives. Included in the list is insulin lispro (Humalog). The ADA encourages the FDA to continue its efforts to spur competition within the insulin landscape, including increasing competition from follow-ons.
Insulin supply chain transparency: The ADA’s working group concluded after discussions with stakeholders that there is an innate lack of transparency throughout the insulin supply chain. Without clear information about insulin pricing and costs to patients, it is difficult to properly identify solutions. Given this fact, the ADA recommends increasing transparency throughout the full supply chain, from manufacturers, wholesalers, pharmacy benefit managers, health plans, and pharmacies.
Health plan design and patient cost-sharing: The ADA recommends that insulins should not be subject to a deductible or coinsurance, because these practices expose patients to high list prices and create barriers to access to medication. The ADA notes that many plans are moving toward a value-based insurance design, and providing diabetes medications with low or no cost-sharing has previously been shown to increase medication adherence and better long-term health outcomes.
Additionally, the ADA recommends that health plans and government programs be required to limit out-of-pocket spending. Specifically, in the Medicare Part D program, the ADA recommends an annual out-of-pocket limit that is equal to the catastrophic phase trigger in order to provide a financial safety net for patients with high drug costs.
Continuity of care: Due to formulary decisions directly impacting insured patients, the ADA recommends that all health plans and government healthcare programs be prohibited from removing medications from their formularies or moving drugs to a higher tier during the plan year (with the exception of cases in which the FDA calls into question the safety of the drug).
“The ADA recommends policymakers take any steps necessary to ensure all people with diabetes have affordable access to insulin, regardless of where they live, whether they have insurance and how much money they earn,” read the policy statement.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.